Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Liet al. find that fructose-1,6-bisphosphatase 1 (FBP1) levels are uniformly reduced in clear cell renal cell carcinoma (ccRCC), identifying a new mechanism of metabolic reprogramming in this cancer type.
Yuet al. show that circulating tumour cells derived from patients with metastatic breast cancer can be used to track tumour evolution and can also be grown in culture to test for drug sensitivities.
Heat shock factor 1 (HSF1) in stromal cells promotes both reprogramming of cancer cell gene expression and activation of a transcriptional programme in stromal cells that potentiates malignancy in neighbouring tumour cells.
Hartwellet al. show that the oestrogen-responsive pituitary hormone prolactin might cause some of the gender bias in hepatocellular carcinoma (HCC) development, and therapeutic activation of prolactin signalling might reduce HCC risk.
The unfolded protein response (UPR) is an important pro-survival pathway that is often activated in tumour cells owing to endoplasmic reticulum stress that is caused by both intrinsic and extrinsic factors. Wang and Kaufman discuss the mechanisms of UPR activation in tumour cells, the importance of this pathway to cancer development and targeting strategies for therapeutic intervention.
Focal adhesion kinase (FAK) can promote tumour growth and metastasis through various kinase-dependent and kinase-independent pathways. This Review discusses the roles of FAK in tumour cells and cells of the microenvironment, as well as the progress that is being made in the clinical development of FAK inhibitors.
Disseminated tumour cells that survive treatment may become dormant and their 'awakening' may be the source of metastases. This Review discusses the mechanisms and factors that regulate tumour dormancy, including the extracellular and stromal microenvironments, autophagy and epigenetics. The authors also discuss how this information could be used therapeutically for metastatic disease.
Circulating tumour cells (CTCs) are the subject of many published papers, but the diversity of assays used for their analysis can be daunting. This Opinion article discusses issues regarding the detection and characterization of CTCs, and poses the major outstanding questions in this field.
In this Opinion article, Buchheitet al. describe the cellular changes that regulate cell viability when cells become detached from the ECM. In particular, they discuss how cancer cells take advantage of these specific processes and how better understanding them will be instrumental in designing therapeutic strategies that aim to eliminate ECM-detached metastatic cells.
